Lenalidomide

REVLIMID®

Overview

Lenalidomide is a cancer medicine that promotes an immune response to help slow tumor growth. It is given as an oral medication.

SparkCures ID 3
Developed By Celgene Corporation
Brand Name Revlimid®
Generic Name Lenalidomide
Additional Names CC-5013
Treatment Classifications
Tags
  • FDA Approved

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Smoldering Myeloma

The following is a listing of clinical trials for patients with Smoldering Myeloma.

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Lenalidomide Shown to Reduce the Risk of Progression in Smoldering Multiple Myeloma

May 24, 2019

Lenalidomide reduced the risk of disease progression among patients with intermediate- or high-risk smoldering multiple myeloma, according to data from the phase 2/3 E3A06 clinical trial. The trial results will be presented at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

The trial had a phase 2/3 design and enrolled patients with intermediate- or high-risk smoldering multiple myeloma. For the phase 2 portion, a single group of 44 patients received lenalidomide.

Once the safety of lenalidomide was demonstrated in the phase 2 portion, a phase 3 study was conducted, and patients were randomly assigned to either the lenalidomide arm (90 patients) or observation arm (92 patients). Patients enrolled in the intervention arm received lenalidomide 25 mg orally each day for 21 days of the first 28 days of a treatment cycle.

In the phase 2 portion of the trial, 87% of participants were still alive without disease progression at 3 years of follow-up. In the randomized phase 3 portion, 91% of patients remained alive without disease progression in the lenalidomide arm compared with 66% in the observation arm at 3 years of follow-up.

Resources